Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

OSB Group appoints Victoria Hyde as CFO

(Sharecast News) - OSB Group said on Friday that it has appointed Victoria Hyde as its new chief financial officer and executive director with effect from 10 May. Hyde joined OSBG as deputy CFO in September 2022, specifically as part of the board's executive succession planning.

Prior to that, during a 21-year career at Barclays, she undertook several complex roles across product control, Treasury finance and financial planning and analysis. Most recently, she served as finance director of the Barclays consumer, cards and payments businesses.

Hyde will succeed April Talintyre, whose intention to retire was announced in November last year. Talintyre will step down from the board at the annual general meeting on 9 May.

Chairman David Weymouth said: "I am delighted that Victoria has accepted the role and will be able to bring to bear her wealth of experience from a successful career in senior roles, which will be both relevant and important in helping lead the next phase of development at OSB."

Share this article

Related Sharecast Articles

UBS to book $900m provision over Greensill supply financing funds
(Sharecast News) - Swiss banking giant UBS announced on Monday that it expected to book a provision of about $900m related to Credit Suisse's funds, tied to the collapsed supply chain financing firm Greensill Capital.
Citi downgrades European equities to 'neutral'
(Sharecast News) - Citi downgraded its stance on European equities on Monday to 'neutral' from 'overweight' as it said near-term risks have increased, with markets narrowing and political uncertainty taking centre stage.
Hutchmed publishes positive sovleplenib trial results
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.
Somero trading in line with expectations
(Sharecast News) - Somero Enterprises said in an update on Monday that trading for the first five months of 2024 was consistent with expectations.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.